Effects of COVID-19 on the Musculoskeletal System: Clinician’s Guide

References

• Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506. doi:10.1016/s0140-6736(20)30183-5
   PubMed Web of Science ®Google Scholar
• Sun P, Qie S, Liu Z, Ren J, Li K, Xi J. Clinical characteristics of hospitalized patients with SARS-CoV-2 infection: a single arm meta-analysis. J Med Virol. 2020;92(6):612–617. doi:10.1002/jmv.25735
   PubMed Web of Science ®Google Scholar
• White-Dzuro G, Gibson LE, Zazzeron L, et al. Multisystem effects of COVID-19: a concise review for practitioners. Postgrad Med. 2021;133(1):20–27. doi:10.1080/00325481.2020.1823094
   PubMed Web of Science ®Google Scholar
• Zhu J, Ji P, Pang J, et al. Clinical characteristics of 3062 COVID-19 patients: a meta-analysis. J Med Virol. 2020;92(10):1902–1914. doi:10.1002/jmv.25884
   PubMed Web of Science ®Google Scholar
• Shen J, Abu-Amer Y, O’Keefe RJ, McAlinden A. Inflammation and epigenetic regulation in osteoarthritis. Connect Tissue Res. 2017;58(1):49–63. doi:10.1080/03008207.2016.1208655
   PubMed Web of Science ®Google Scholar
• Scanzello CR. Chemokines and inflammation in osteoarthritis: insights from patients and animal models. J Orthop Res. 2017;35(4):735–739. doi:10.1002/jor.23471
   PubMed Web of Science ®Google Scholar
• Redlich K, Smolen JS. Inflammatory bone loss: pathogenesis and therapeutic intervention. Nat Rev Drug Discov. 2012;11(3):234–250. doi:10.1038/nrd3669
   PubMed Web of Science ®Google Scholar
• Parasher A. COVID-19: current understanding of its pathophysiology, clinical presentation and treatment. Postgrad Med J. 2021;97(1147):312–320. doi:10.1136/postgradmedj-2020-138577
   PubMed Web of Science ®Google Scholar
• Mehta OP, Bhandari P. Coronavirus Disease (COVID-19): Comprehensive Review of Clinical Presentation. Front Public Health. 2020;8(2):582932. doi:10.3389/fpubh.2020.582932
   Web of Science ®Google Scholar
• Disser NP, De Micheli AJ, Schonk MM, et al. Musculoskeletal consequences of COVID-19. J Bone Joint Surg Am. 2020;102(14):1197–1204. doi:10.2106/jbjs.20.00847
   PubMed Web of Science ®Google Scholar
• Jin Y, Yang H, Ji W, et al. Virology, epidemiology, pathogenesis, and control of COVID-19. Viruses. 2020;12(4):372. doi:10.3390/v12040372
   PubMed Web of Science ®Google Scholar
• Tay MZ, Poh CM, Rénia L, MacAry PA, Ng LFP. The trinity of COVID-19: immunity, inflammation and intervention. Nat Rev Immunol. 2020;20(6):363–374. doi:10.1038/s41577-020-0311-8
   PubMed Web of Science ®Google Scholar
• Lin L, Lu L, Cao W, Li T. Hypothesis for potential pathogenesis of SARS-CoV-2 infection-a review of immune changes in patients with viral pneumonia. Emerg Microbes Infect. 2020;9(1):727–732. doi:10.1080/22221751.2020.1746199
   PubMed Web of Science ®Google Scholar
• Perandini LA, Chimin P, Lutkemeyer DDS, Câmara NOS. Chronic inflammation in skeletal muscle impairs satellite cells function during regeneration: can physical exercise restore the satellite cell niche? FEBS J. 2018;285(11):1973–1984. doi:10.1111/febs.14417
   Web of Science ®Google Scholar
• Hanaoka BY, Ithurburn MP, Rigsbee CA, et al. Chronic inflammation in rheumatoid arthritis and mediators of skeletal muscle pathology and physical impairment: a review. Arthritis Care Res (Hoboken). 2019;71(2):173–177. doi:10.1002/acr.23775
   Web of Science ®Google Scholar
• Doughty CT, Amato AA. Toxic myopathies. Continuum (Minneap Minn). 2019;25(6):1712–1731. doi:10.1212/con.0000000000000806
   Google Scholar
• McClafferty B, Umer I, Fye G, et al. Approach to critical illness myopathy and polyneuropathy in the older SARS-CoV-2 patients. J Clin Neurosci. 2020;79:241–245. doi:10.1016/j.jocn.2020.07.058
   Web of Science ®Google Scholar
• Cabañes-Martínez L, Villadóniga M, González-Rodríguez L, et al. Neuromuscular involvement in COVID-19 critically ill patients. Clin Neurophysiol. 2020;131(12):2809–2816. doi:10.1016/j.clinph.2020.09.017
   Web of Science ®Google Scholar
• Abdullahi A, Candan SA, Abba MA, et al. Neurological and musculoskeletal features of COVID-19: a systematic review and meta-analysis. Front Neurol. 2020;11:687. doi:10.3389/fneur.2020.00687
   PubMed Web of Science ®Google Scholar
• Tankisi H, Tankisi A, Harbo T, Markvardsen LK, Andersen H, Pedersen TH. Critical illness myopathy as a consequence of Covid-19 infection. Clin Neurophysiol. 2020;131(8):1931–1932. doi:10.1016/j.clinph.2020.06.003
   PubMed Web of Science ®Google Scholar
• Nasuelli NA, Pettinaroli R, Godi L, et al. Critical illness neuro-myopathy (CINM) and focal amyotrophy in intensive care unit (ICU) patients with SARS-CoV-2: a case series. Neurol Sci. 2021;42(3):1119–1121. doi:10.1007/s10072-020-04820-9
   Web of Science ®Google Scholar
• Yang T, Li Z, Jiang L, Wang Y, Xi X. Risk factors for intensive care unit-acquired weakness: a systematic review and meta-analysis. Acta Neurol Scand. 2018;138(2):104–114. doi:10.1111/ane.12964
   PubMed Web of Science ®Google Scholar
• Vanhorebeek I, Latronico N, Van den Berghe G. ICU-acquired weakness. Intensive Care Med. 2020;46(4):637–653. doi:10.1007/s00134-020-05944-4
   PubMed Web of Science ®Google Scholar
• Bellido V, Pérez A. Inpatient hyperglycemia management and COVID-19. Diabetes Ther. 2021;12(1):121–132. doi:10.1007/s13300-020-00966-z
   Web of Science ®Google Scholar
• Wunsch H. Mechanical ventilation in COVID-19: interpreting the current epidemiology. Am J Respir Crit Care Med. 2020;202(1):1–4. doi:10.1164/rccm.202004-1385ED
   PubMed Web of Science ®Google Scholar
• Iwasaki M, Saito J, Zhao H, Sakamoto A, Hirota K, Ma D. Inflammation triggered by SARS-CoV-2 and ACE2 augment drives multiple organ failure of severe COVID-19: molecular mechanisms and implications. Inflammation. 2021;44(1):13–34. doi:10.1007/s10753-020-01337-3
   PubMed Web of Science ®Google Scholar
• Thibault R, Seguin P, Tamion F, Pichard C, Singer P. Nutrition of the COVID-19 patient in the intensive care unit (ICU): a practical guidance. Crit Care. 2020;24(1):447. doi:10.1186/s13054-020-03159-z
   Web of Science ®Google Scholar
• Hu B, Huang S, Yin L. The cytokine storm and COVID-19. J Med Virol. 2021;93(1):250–256. doi:10.1002/jmv.26232
   PubMed Web of Science ®Google Scholar
• Van Aerde N, Van den Berghe G, Wilmer A, Gosselink R, Hermans G. Intensive care unit acquired muscle weakness in COVID-19 patients. Intensive Care Med. 2020;46(11):2083–2085. doi:10.1007/s00134-020-06244-7
   PubMed Web of Science ®Google Scholar
• Wieske L, Dettling-Ihnenfeldt DS, Verhamme C, et al. Impact of ICU-acquired weakness on post-ICU physical functioning: a follow-up study. Crit Care. 2015;19(1):196. doi:10.1186/s13054-015-0937-2
   Web of Science ®Google Scholar
• Anekwe DE, Biswas S, Bussières A, Spahija J. Early rehabilitation reduces the likelihood of developing intensive care unit-acquired weakness: a systematic review and meta-analysis. Physiotherapy. 2020;107:1–10. doi:10.1016/j.physio.2019.12.004
   PubMed Web of Science ®Google Scholar
• Agosti E, Giorgianni A, D’Amore F, Vinacci G, Balbi S, Locatelli D. Is Guillain-Barrè syndrome triggered by SARS-CoV-2? Case report and literature review. Neurol Sci. 2021;42(2):607–612. doi:10.1007/s10072-020-04553-9
   PubMed Web of Science ®Google Scholar
• Alberti P, Beretta S, Piatti M, et al. Guillain-Barré syndrome related to COVID-19 infection. Neurol Neuroimmunol Neuroinflamm. 2020;7(4):e741. doi:10.1212/nxi.0000000000000741
   PubMed Web of Science ®Google Scholar
• Arnaud S, Budowski C, Ng Wing Tin S, Degos B. Post SARS-CoV-2 Guillain-Barré syndrome. Clin Neurophysiol. 2020;131(7):1652–1654. doi:10.1016/j.clinph.2020.05.003
   PubMed Web of Science ®Google Scholar
• Assini A, Benedetti L, Di Maio S, Schirinzi E, Del Sette M. New clinical manifestation of COVID-19 related Guillain-Barrè syndrome highly responsive to intravenous immunoglobulins: two Italian cases. Neurol Sci. 2020;41(7):1657–1658. doi:10.1007/s10072-020-04484-5
   PubMed Web of Science ®Google Scholar
• Bigaut K, Mallaret M, Baloglu S, et al. Guillain-Barré syndrome related to SARS-CoV-2 infection. Neurol Neuroimmunol Neuroinflamm. 2020;7(5):e785. doi:10.1212/nxi.0000000000000785
   PubMed Web of Science ®Google Scholar
• Abu-Rumeileh S, Abdelhak A, Foschi M, Tumani H, Otto M. Guillain-Barré syndrome spectrum associated with COVID-19: an up-to-date systematic review of 73 cases. J Neurol. 2021;268(4):1133–1170. doi:10.1007/s00415-020-10124-x
   PubMed Web of Science ®Google Scholar
• Sejvar JJ, Baughman AL, Wise M, Morgan OW. Population incidence of Guillain-Barré syndrome: a systematic review and meta-analysis. Neuroepidemiology. 2011;36(2):123–133. doi:10.1159/000324710
   PubMed Web of Science ®Google Scholar
• Paliwal VK, Garg RK, Gupta A, Tejan N. Neuromuscular presentations in patients with COVID-19. Neurol Sci. 2020;41(11):3039–3056. doi:10.1007/s10072-020-04708-8
   PubMed Web of Science ®Google Scholar
• Tao H, Bai J, Zhang W, et al. Bone biology and COVID-19 infection: is ACE2 a potential influence factor? Med Hypotheses. 2020;144:110178. doi:10.1016/j.mehy.2020.110178
   Web of Science ®Google Scholar
• Orford N, Cattigan C, Brennan SL, Kotowicz M, Pasco J, Cooper DJ. The association between critical illness and changes in bone turnover in adults: a systematic review. Osteoporos Int. 2014;25(10):2335–2346. doi:10.1007/s00198-014-2734-1
   Web of Science ®Google Scholar
• Orford NR, Pasco JA, Kotowicz MA. Osteoporosis and the critically ill patient. Crit Care Clin. 2019;35(2):301–313. doi:10.1016/j.ccc.2018.11.006
   Web of Science ®Google Scholar
• Hiraga T. Hypoxic microenvironment and metastatic bone disease. Int J Mol Sci. 2018;19(11):3523. doi:10.3390/ijms19113523
   Web of Science ®Google Scholar
• Tao H, Ge G, Li W, et al. Dysimmunity and inflammatory storm: watch out for bone lesions in COVID-19 infection. Med Hypotheses. 2020;145:110332. doi:10.1016/j.mehy.2020.110332
   Web of Science ®Google Scholar
• Gallardo E, de Andrés I, Illa I. Cathepsins are upregulated by IFN-gamma/STAT1 in human muscle culture: a possible active factor in dermatomyositis. J Neuropathol Exp Neurol. 2001;60(9):847–855. doi:10.1093/jnen/60.9.847
   Web of Science ®Google Scholar
• Authier FJ, Chazaud B, Plonquet A, et al. Differential expression of the IL-1 system components during in vitro myogenesis: implication of IL-1beta in induction of myogenic cell apoptosis. Cell Death Differ. 1999;6(10):1012–1021. doi:10.1038/sj.cdd.4400576
   Web of Science ®Google Scholar
• Forcina L, Miano C, Scicchitano BM, et al. Increased circulating levels of interleukin-6 affect the redox balance in skeletal muscle. Oxid Med Cell Longev. 2019;2019:3018584. doi:10.1155/2019/3018584
   Web of Science ®Google Scholar
• Tang H, Pang S, Wang M, et al. TLR4 activation is required for IL-17-induced multiple tissue inflammation and wasting in mice. J Immunol. 2010;185(4):2563–2569. doi:10.4049/jimmunol.0903664
   Web of Science ®Google Scholar
• Reid MB, Li YP. Tumor necrosis factor-alpha and muscle wasting: a cellular perspective. Respir Res. 2001;2(5):269–272. doi:10.1186/rr67
   PubMed Web of Science ®Google Scholar
• Otis JS, Niccoli S, Hawdon N, et al. Pro-inflammatory mediation of myoblast proliferation. PLoS One. 2014;9(3):e92363. doi:10.1371/journal.pone.0092363
   Web of Science ®Google Scholar
• Gilbert L, He X, Farmer P, et al. Inhibition of osteoblast differentiation by tumor necrosis factor-alpha. Endocrinology. 2000;141(11):3956–3964. doi:10.1210/endo.141.11.7739
   PubMed Web of Science ®Google Scholar
• Kotake S, Udagawa N, Takahashi N, et al. IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J Clin Invest. 1999;103(9):1345–1352. doi:10.1172/jci5703
   PubMed Web of Science ®Google Scholar
• Liu P, Lee S, Knoll J, et al. Loss of menin in osteoblast lineage affects osteocyte-osteoclast crosstalk causing osteoporosis. Cell Death Differ. 2017;24(4):672–682. doi:10.1038/cdd.2016.165
   Web of Science ®Google Scholar
• Grange L, Nguyen MV, Lardy B, et al. NAD(P)H oxidase activity of Nox4 in chondrocytes is both inducible and involved in collagenase expression. Antioxid Redox Signal. 2006;8(9–10):1485–1496. doi:10.1089/ars.2006.8.1485
   Web of Science ®Google Scholar
• Latourte A, Cherifi C, Maillet J, et al. Systemic inhibition of IL-6/Stat3 signalling protects against experimental osteoarthritis. Ann Rheum Dis. 2017;76(4):748–755. doi:10.1136/annrheumdis-2016-209757
   PubMed Web of Science ®Google Scholar
• Aizawa T, Kon T, Einhorn TA, Gerstenfeld LC. Induction of apoptosis in chondrocytes by tumor necrosis factor-alpha. J Orthop Res. 2001;19(5):785–796. doi:10.1016/s0736-0266(00)00078-4
   Web of Science ®Google Scholar
• Zhang K, Asai S, Yu B, Enomoto-Iwamoto M. IL-1β irreversibly inhibits tenogenic differentiation and alters metabolism in injured tendon-derived progenitor cells in vitro. Biochem Biophys Res Commun. 2015;463(4):667–672. doi:10.1016/j.bbrc.2015.05.122
   Web of Science ®Google Scholar
• Millar NL, Akbar M, Campbell AL, et al. IL-17A mediates inflammatory and tissue remodelling events in early human tendinopathy. Sci Rep. 2016;6(1):27149. doi:10.1038/srep27149
   Web of Science ®Google Scholar
• Backman LJ, Eriksson DE, Danielson P. Substance P reduces TNF-α-induced apoptosis in human tenocytes through NK-1 receptor stimulation. Br J Sports Med. 2014;48(19):1414–1420. doi:10.1136/bjsports-2013-092438
   PubMed Web of Science ®Google Scholar
• Mukarram MS, Ishaq Ghauri M, Sethar S, Afsar N, Riaz A, Ishaq K. COVID-19: an emerging culprit of inflammatory arthritis. Case Rep Rheumatol. 2021;2021:6610340. doi:10.1155/2021/6610340
   Google Scholar
• Saricaoglu EM, Hasanoglu I, Guner R. The first reactive arthritis case associated with COVID-19. J Med Virol. 2021;93(1):192–193. doi:10.1002/jmv.26296
   Web of Science ®Google Scholar
• Ono K, Kishimoto M, Shimasaki T, et al. Reactive arthritis after COVID-19 infection. RMD Open. 2020;6(2):e001350. doi:10.1136/rmdopen-2020-001350
   Web of Science ®Google Scholar
• Mukarram I, Mukarram M, Ishaq K, Riaz S. Post COVID-19 reactive arthritis: an emerging existence in the spectrum of musculoskeletal complications of SARS-CoV-2 infection. J Clin Stud Med Case Rep. 2020;7(101):2.
   Google Scholar
• Campochiaro C, Della-Torre E, Cavalli G, et al. Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study. Eur J Intern Med. 2020;76:43–49. doi:10.1016/j.ejim.2020.05.021
   PubMed Web of Science ®Google Scholar
• Biggioggero M, Crotti C, Becciolini A, Favalli EG. Tocilizumab in the treatment of rheumatoid arthritis: an evidence-based review and patient selection. Drug Des Devel Ther. 2019;13:57–70. doi:10.2147/dddt.S150580
   PubMed Web of Science ®Google Scholar
• Xu X, Han M, Li T, et al. Effective treatment of severe COVID-19 patients with tocilizumab. Proc Natl Acad Sci U S A. 2020;117(20):10970–10975. doi:10.1073/pnas.2005615117
   PubMed Web of Science ®Google Scholar
• Tuzun S, Keles A, Okutan D, Yildiran T, Palamar D. Assessment of musculoskeletal pain, fatigue and grip strength in hospitalized patients with COVID-19. Eur J Phys Rehabil Med. 2021;57(4):653–662. doi:10.23736/s1973-9087.20.06563-6
   Web of Science ®Google Scholar
• Hoong CWS, Amin M, Tan TC, Lee JE. Viral arthralgia a new manifestation of COVID-19 infection? A cohort study of COVID-19-associated musculoskeletal symptoms. Int J Infect Dis. 2021;104:363–369. doi:10.1016/j.ijid.2021.01.031
   PubMed Web of Science ®Google Scholar
• Carfì A, Bernabei R, Landi F. Persistent symptoms in patients after acute COVID-19. JAMA. 2020;324(6):603–605. doi:10.1001/jama.2020.12603
   PubMed Web of Science ®Google Scholar
• Greenhalgh T, Knight M, A’Court C, Buxton M, Husain L. Management of post-acute covid-19 in primary care. BMJ. 2020;370:m3026. doi:10.1136/bmj.m3026
   PubMed Web of Science ®Google Scholar
• De Rosa A, Verrengia EP, Merlo I, et al. Muscle manifestations and CK levels in COVID infection: results of a large cohort of patients inside a pandemic COVID-19 area. Acta Myol. 2021;40(1):1–7. doi:10.36185/2532-1900-040
   Google Scholar
• Cummings MJ, Baldwin MR, Abrams D, et al. Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a Prospective Cohort Study. Lancet. 2020;395(10239):1763–1770. doi:10.1016/s0140-6736(20)31189-2
   PubMed Web of Science ®Google Scholar
• Lechien JR, Chiesa-Estomba CM, Place S, et al. Clinical and epidemiological characteristics of 1420 European patients with mild-to-moderate coronavirus disease 2019. J Intern Med. 2020;288(3):335–344. doi:10.1111/joim.13089
   PubMed Web of Science ®Google Scholar
• McCray PB Jr, Pewe L, Wohlford-Lenane C, et al. Lethal infection of K18-hACE2 mice infected with severe acute respiratory syndrome coronavirus. J Virol. 2007;81(2):813–821. doi:10.1128/jvi.02012-06
   PubMed Web of Science ®Google Scholar
• Leung TW, Wong KS, Hui AC, et al. Myopathic changes associated with severe acute respiratory syndrome: a postmortem case series. Arch Neurol. 2005;62(7):1113–1117. doi:10.1001/archneur.62.7.1113
   PubMedGoogle Scholar
• Ding Y, Wang H, Shen H, et al. The clinical pathology of severe acute respiratory syndrome (SARS): a report from China. J Pathol. 2003;200(3):282–289. doi:10.1002/path.1440
   PubMed Web of Science ®Google Scholar
• Lv H, de Vlas SJ, Liu W, et al. Avascular osteonecrosis after treatment of SARS: a 3-Year Longitudinal Study. Trop Med Int Health. 2009;14 Suppl 1(Suppl1):79–84. doi:10.1111/j.1365-3156.2008.02187.x
   Web of Science ®Google Scholar
• Guo KJ, Zhao FC, Guo Y, Li FL, Zhu L, Zheng W. The influence of age, gender and treatment with steroids on the incidence of osteonecrosis of the femoral head during the management of severe acute respiratory syndrome: a retrospective study. Bone Joint J. 2014;96-b(2):259–262. doi:10.1302/0301-620x.96b2.31935
   PubMed Web of Science ®Google Scholar
• Griffith JF. Musculoskeletal complications of severe acute respiratory syndrome. Semin Musculoskelet Radiol. 2011;15(5):554–560. doi:10.1055/s-0031-1293500
   PubMed Web of Science ®Google Scholar
• Zhou J, Liu B, Liang C, Li Y, Song YH. Cytokine signaling in skeletal muscle wasting. Trends Endocrinol Metab. 2016;27(5):335–347. doi:10.1016/j.tem.2016.03.002
   PubMed Web of Science ®Google Scholar
• Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB. Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review. JAMA. 2020;323(18):1824–1836. doi:10.1001/jama.2020.6019
   PubMed Web of Science ®Google Scholar
• Munschauer FE 3rd, Kinkel RP. Managing side effects of interferon-beta in patients with relapsing-remitting multiple sclerosis. Clin Ther. 1997;19(5):883–893. doi:10.1016/s0149-2918(97)80042-2
   Web of Science ®Google Scholar
• Nikfar S, Rahimi R, Abdollahi M. A meta-analysis of the efficacy and tolerability of interferon-β in multiple sclerosis, overall and by drug and disease type. Clin Ther. 2010;32(11):1871–1888. doi:10.1016/j.clinthera.2010.10.006
   PubMed Web of Science ®Google Scholar
• Dusheiko G. Side effects of alpha interferon in chronic hepatitis C. Hepatology. 1997;26(3Suppl 1):112s–121s. doi:10.1002/hep.510260720
   Web of Science ®Google Scholar
• Psarras A, Emery P, Vital EM. Type I interferon-mediated autoimmune diseases: pathogenesis, diagnosis and targeted therapy. Rheumatology (Oxford). 2017;56(10):1662–1675. doi:10.1093/rheumatology/kew431
   Web of Science ®Google Scholar
• Casado E, Gratacós J, Tolosa C, et al. Antimalarial myopathy: an underdiagnosed complication? Prospective longitudinal study of 119 patients. Ann Rheum Dis. 2006;65(3):385–390. doi:10.1136/ard.2004.023200
   PubMed Web of Science ®Google Scholar
• Chandwani A, Shuter J. Lopinavir/ritonavir in the treatment of HIV-1 infection: a review. Ther Clin Risk Manag. 2008;4(5):1023–1033. doi:10.2147/tcrm.s3285
   PubMedGoogle Scholar
• Naik GS, Tyagi MG. A pharmacological profile of ribavirin and monitoring of its plasma concentration in chronic hepatitis C infection. J Clin Exp Hepatol. 2012;2(1):42–54. doi:10.1016/s0973-6883(12)60090-5
   Google Scholar
• Oh TK, Song IA, Lee J, Eom W, Jeon YT. Musculoskeletal disorders, pain medication, and in-hospital mortality among patients with COVID-19 in South Korea: a Population-Based Cohort Study. Int J Environ Res Public Health. 2021;18(13):6804. doi:10.3390/ijerph18136804
   Web of Science ®Google Scholar
• van Paassen J, Vos JS, Hoekstra EM, Neumann KMI, Boot PC, Arbous SM. Corticosteroid use in COVID-19 patients: a systematic review and meta-analysis on clinical outcomes. Crit Care. 2020;24(1):696. doi:10.1186/s13054-020-03400-9
   PubMed Web of Science ®Google Scholar
• Lau EM, Chan FW, Hui DS, Wu AK, Leung PC. Reduced bone mineral density in male Severe Acute Respiratory Syndrome (SARS) patients in Hong Kong. Bone. 2005;37(3):420–424. doi:10.1016/j.bone.2005.04.018
   PubMed Web of Science ®Google Scholar
• Karaarslan F, Demircioğlu Güneri F, Kardeş S. Postdischarge rheumatic and musculoskeletal symptoms following hospitalization for COVID-19: prospective follow-up by phone interviews. Rheumatol Int. 2021;41(7):1263–1271. doi:10.1007/s00296-021-04882-8
   Web of Science ®Google Scholar
• Arnold DT, Hamilton FW, Milne A, et al. Patient outcomes after hospitalisation with COVID-19 and implications for follow-up: results from a prospective UK cohort. Thorax. 2021;76(4):399–401. doi:10.1136/thoraxjnl-2020-216086
   PubMed Web of Science ®Google Scholar
• Lau HM, Ng GY, Jones AY, Lee EW, Siu EH, Hui DS. A randomised controlled trial of the effectiveness of an exercise training program in patients recovering from severe acute respiratory syndrome. Aust J Physiother. 2005;51(4):213–219. doi:10.1016/s0004-9514(05)70002-7
   PubMed Web of Science ®Google Scholar
• Rooney S, Webster A, Paul L. Systematic review of changes and recovery in physical function and fitness after severe acute respiratory syndrome-related coronavirus infection: implications for COVID-19 rehabilitation. Phys Ther. 2020;100(10):1717–1729. doi:10.1093/ptj/pzaa129
   PubMed Web of Science ®Google Scholar
• Mulcahey MK, Gianakos AL, Mercurio A, Rodeo S, Sutton KM. Sports medicine considerations during the COVID-19 pandemic. Am J Sports Med. 2021;49(2):512–521. doi:10.1177/0363546520975186
   PubMed Web of Science ®Google Scholar
• Hosseiny M, Kooraki S, Gholamrezanezhad A, Reddy S, Myers L. Radiology perspective of coronavirus disease 2019 (COVID-19): lessons from severe acute respiratory syndrome and middle east respiratory syndrome. AJR Am J Roentgenol. 2020;214(5):1078–1082. doi:10.2214/ajr.20.22969
   PubMed Web of Science ®Google Scholar